Blinatumomab alternating with LIC in older adults with newly diagnosed B-ALL – ALL Hub

ALL Hub shared a post on X:

“CONGRESS | POSTER | EHA2024 | Elias Jabbour from MD Anderson Cancer Center reports follow-up for the phase III Golden Gate Study of blinatumomab alternating with low-intensity chemotherapy (LIC) in older adults with ND B-ALL. 13/14 (92.9%) patients had CR with blinatumomab and alternating LIC at the end of induction (~Week 14), 84.6% of these were MRD-negative. Acceptable safety profile.”

Source: ALL Hub/X